EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Organ Donor Pretreatment With Anti-Thymocyte Globulin in a Murine Model of Allogenic Kidney Transplantation

An He, Yiren Yang, Katja Kotsch, Arne Sattler

Transplant International · 2025

DOI: 10.3389/ti.2024.13997 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von An He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Dep…. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Kidney Transplantation, Immunosuppressive Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney transplantation is the treatment of choice for end-stage organ failure. To improve transplantation outcomes, particularly of “marginal” organs from extended criteria donors (ECD), attempts have been made to therapeutically modulate donor or graft pre-transplantation. Anti-thymocyte globulin (ATG) has a history as lymphocyte-depleting, immunosuppressive drug for treating rejection episodes post transplantation. In this study, however, we aimed to comprehensively analyze the effects of ATG donor pre-conditioning in a mouse model of kidney transplantation. ATG pre-treatment of potential donors led to a broad depletion of T- and NK cells in peripheral blood, non-lymphoid (including kidney) and lymphoid organs within 48 h, whereas myeloid cells were spared. ATG was also effectively depleting renal innate lymphoid type 1 and 2 cells. Importantly, transplantation of kidneys from ATG pre-treated donors into fully mismatched recipients showed only mild effects on leukocyte re-composition post transplantation. In line with this, serum creatinine and urea levels were similar in animals receiving kidneys from ATG treated donors or controls, demonstrating that donor treatment had no effect on allograft function in the early post-transplantation phase. In summary, our findings are suggestive of a more cell-type-specific depletion strategy in concert with an experimental model better reflecting aspects of clinical transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumKidney TransplantationImmunosuppressive AgentsAnimalsMiceMaleTissue DonorsMice, Inbred C57BLMice, Inbred BALB CTransplantation, HomologousGraft SurvivalGraft RejectionCreatinineKiller Cells, Natural

Stichwörter der Autor:innen

anti-thymocyte globulindonor pre-treatmentkidney functionkidney transplantationpassenger leukocytes

Substanzen

Antilymphocyte SerumImmunosuppressive AgentsCreatinine

Autor:innen und Institutionen

  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department for General and Visceral Surgery, Berlin, Germany.
  • Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Zitieren

APA

He, A., Yang, Y., Kotsch, K., & Sattler, A. (2025). Impact of Organ Donor Pretreatment With Anti-Thymocyte Globulin in a Murine Model of Allogenic Kidney Transplantation. Transplant International. https://doi.org/10.3389/ti.2024.13997

Vancouver

He A, Yang Y, Kotsch K, Sattler A. Impact of Organ Donor Pretreatment With Anti-Thymocyte Globulin in a Murine Model of Allogenic Kidney Transplantation. Transplant International. 2025. doi:10.3389/ti.2024.13997

BibTeX
@article{He2025,
  author = {He, An and Yang, Yiren and Kotsch, Katja and Sattler, Arne},
  title = {Impact of Organ Donor Pretreatment With Anti-Thymocyte Globulin in a Murine Model of Allogenic Kidney Transplantation},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2024.13997}
}
Kostenlos starten →